Fenofibrate and Pioglitazone Do Not Ameliorate the Altered Vascular Reactivity in Aorta of Isoproterenol-treated Rats


Autoria(s): FUKUDA, Livia Emy; DAVEL, Ana Paula Couto; VERISSIMO-FILHO, Sidney; LOPES, Lucia Rossetti; CACHOFEIRO, Victoria; LAHERA, Vicente; ROSSONI, Luciana Venturini
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2008

Resumo

Chronic stimulation of beta-adrenoceptors with isoproterenol induces alteration of vascular reactivity and increases local proinflammatory cytokines. We investigated whether fenofibrate and pioglitazone, PPAR-alpha and -gamma agonists, respectively, improve the changes in vascular reactivity induced by isoproterenol. Wistar rats received isoproterenol (0.3 mg.kg(-1).day(-1), SC) or vehicle (CT) plus fenofibrate (alpha, 100 mg.kg(-1).day(-1), PO), pioglitazone (gamma, 2.5 mg.kg(-1).day(-1), PO), or water for 7 days. In aortas, isoproterenol treatment enhanced the maximal response (Rmax) to phenylephrine (10(-10) to 10(-4) M) compared to CT as previously demonstrated. The effects of endothelium removal (E-) or L-NAME incubation (100 mu M) on the phenylephrine response were smaller in isoproterenol-treated animals compared to CT while superoxide dismutase (SOD, 150 U/mL) significantly reduced the Rmax to phenylephrine to CT levels. Neither fenofibrate nor pioglitazone changed the effects induced by isoproterenol in aorta. E-, L-NAME, or SOD effects were similar between CT alpha and CT. However, pioglitazone per se increased Rmax to phenylephrine (CT: 59 +/- 4 versus CT gamma: 72 +/- 5 % of contraction to KCl). E- or L-NAME effects were reduced in CT gamma compared to CT, and SOD normalized the altered reactivity to phenylephrine in the CT gamma group. In conclusion, neither fenofibrate nor pioglitazone ameliorates the altered vascular reactivity present in aorta from isoproterenol-treated rats. Moreover, pioglitazone per se induced endothelial dysfunction and increased phenylephrine-induced contraction in aorta.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico a Tecnologico (CNPq)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Identificador

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, v.52, n.5, p.413-421, 2008

0160-2446

http://producao.usp.br/handle/BDPI/28599

http://apps.isiknowledge.com/InboundService.do?Func=Frame&product=WOS&action=retrieve&SrcApp=EndNote&UT=000261528100005&Init=Yes&SrcAuth=ResearchSoft&mode=FullRecord

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

Relação

Journal of Cardiovascular Pharmacology

Direitos

restrictedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #isoproterenol #aorta #endothelium #PPAR #fenofibrate #pioglitazone #PROLIFERATOR-ACTIVATED RECEPTORS #SMOOTH-MUSCLE-CELLS #RESTORES ENDOTHELIAL FUNCTION #PPAR-GAMMA ACTIVATORS #INDUCED DIABETIC-RATS #II-INFUSED RATS #NITRIC-OXIDE #INFLAMMATORY MEDIATORS #MYOCARDIAL-INFARCTION #INDUCED HYPERTENSION #Cardiac & Cardiovascular Systems #Pharmacology & Pharmacy
Tipo

article

original article

publishedVersion